



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

		Application Number	10/813,859
		Filing Date	March 31, 2004
		First Named Inventor	NICOLETTE, Charles A.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission	10	Attorney Docket Number	5032US-DIV

ENCLOSURES (check all that apply)

Fee Transmittal Form
 Fee Attached
 Amendment Reply
 After Final
 Affidavits/declaration(s)
 Extension of Time Request
 Express Abandonment Request
 Information Disclosure Statement
 Certified Copy of Priority Document(s)
 Response to Missing Parts/ Incomplete Application
 Response to Missing Parts under 37 CFR 1.52 or 1.53

Drawing(s)
 Licensing-related Papers
 Petition
 Petition to Convert to a Provisional Application
 Power of Attorney, Revocation Change of Correspondence Address
 Terminal Disclaimer
 Request for Refund
 CD, Number of CD(s) _____

After Allowance Communication to Group
 Appeal Communication to Board of Appeals and Interferences
 Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
 Proprietary Information
 Status Letter
 Other Enclosure(s)
(please identify below):

Computer Readable format of the sequence Listing (7 sheets); compact disc copy (1 cd); copy of Notice to Comply (2 sheets); and return postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Deborah A. Dugan Registration No. 37,315 GENZYME CORPORATION
Signature	
Date	11/08/04

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	TARYN ANTALEK	Date
Signature		Nov. 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 110)

Complete if Known	
Application Number	10/813,859
Filing Date	March 31, 2004
First Named Inventor	NICOLETTE, Charles A.
Examiner Name	Unassigned
Art Unit	Unassigned
Attorney Docket No.	5032US-DIV

METHOD OF PAYMENT (check all that apply)

 Check Credit card Money Other None
Order
 Deposit Account:

Deposit Account Number

Deposit Account Name

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	<input type="text"/>
1002	340	2002	170	Design filing fee	<input type="text"/>
1003	530	2003	265	Plant filing fee	<input type="text"/>
1004	770	2004	385	Reissue filing fee	<input type="text"/>
1005	160	2005	80	Provisional filing fee	<input type="text"/>

SUBTOTAL (1)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	<input type="text"/>	-20 **	= <input type="text" value="0"/>	X <input type="text"/>	= <input type="text" value="0"/>
Independent Claims	<input type="text"/>	-3 **	= <input type="text" value="0"/>	X <input type="text"/>	= <input type="text" value="0"/>
Multiple Dependent				X <input type="text"/>	= <input type="text" value="0"/>

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

*or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Small Entity


Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	<input type="text"/>
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	<input type="text"/>
1053	130	1053	130	Non-English specification	<input type="text"/>
1812	2,520	1812	2,520	For filing a request for reexamination	<input type="text"/>
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	<input type="text"/>
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	<input type="text"/>
1251	110	2251	55	Extension for reply within first month	110
1252	420	2252	210	Extension for reply within second month	<input type="text"/>
1253	950	2253	475	Extension for reply within third month	<input type="text"/>
1254	1,480	2254	740	Extension for reply within fourth month	<input type="text"/>
1255	2,010	2255	1,005	Extension for reply within fifth month	<input type="text"/>
1401	330	2401	165	Notice of Appeal	<input type="text"/>
1402	330	2402	165	Filing a brief in support of an appeal	<input type="text"/>
1403	290	2403	145	Request for oral hearing	<input type="text"/>
1451	1,510	1451	1,510	Petition to institute a public use proceeding	<input type="text"/>
1452	110	2452	55	Petition to revive – unavoidable	<input type="text"/>
1453	1,330	2453	665	Petition to revive – unintentional	<input type="text"/>
1501	1,330	2501	665	Utility issue fee (or reissue)	<input type="text"/>
1502	480	2502	240	Design issue fee	<input type="text"/>
1503	640	2503	320	Plant issue fee	<input type="text"/>
1460	130	1460	130	Petitions to the Commissioner	<input type="text"/>
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	<input type="text"/>
1806	180	1806	180	Submission of Information Disclosure Stmt	<input type="text"/>
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	<input type="text"/>
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	<input type="text"/>
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	<input type="text"/>
1801	770	2801	385	Request for Continued Examination (RCE)	<input type="text"/>
1802	900	1802	900	Request for expedited examination of a design application	<input type="text"/>

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

SUBMITTED BY

Complete if applicable					
Name (Print/Type)	Deborah A. Dugan	Registration No. (Attorney/Agent)	37,315	Telephone	508-270-2598
Signature					

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT
Attorney Docket No. 5032US-DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Nicolette, Charles A.

APPLICATION NO: 10/813,859

GROUP NO: Unassigned

FILING DATE: March 31, 2004

EXAMINER: Unassigned

TITLE: THERAPEUTIC COMPOUNDS FOR OVARIAN CANCER

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this paper or fee is being deposited on November 8, 2004 with the United States Postal Service as "First-Class Mail" service under 37 C.F.R. § 1.8(a) and is addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

November 8, 2004
Date

Taryn Antalek
Taryn Antalek

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Responsive to the paper mailed from the United States Patent and Trademark Office on August 6, 2004 and pursuant to 37 C.F.R. §§ 1.821 – 1.824, Applicant submits herewith a paper copy and a computer readable copy of the Sequence Listing for the above-identified application. A copy of the Notice is also attached. As part of this response, Applicant is filing a Petition a One (1) Month Extension of Time, thereby extending the deadline to file a response to the October 6, 2004 Communication to November 6, 2004. Accordingly, this response is timely filed.

Statement


I hereby state that (a) the content of the paper and computer readable copy submitted herewith are the same; (b) the content of the computer readable copy submitted herewith is the same as the Sequence Listing in the original specification; and (c) this submission includes no new matter.

It is believed that no additional fee is required for the timely submission of this paper. If a fee is required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 07-1074.


Respectfully submitted,

11/08/04

Date


Deborah A. Dugan
Registration No. 37,315

Genzyme Corporation
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322
Telephone: (508) 270-2598
Facsimile: (508) 872-5415



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/813,859	03/31/2004	Charles A. Nicolette	5032US-DIV

24536
GENZYME CORPORATION
LEGAL DEPARTMENT
15 PLEASANT ST CONNECTOR
FRAMINGHAM, MA 01701-9322

CONFIRMATION NO. 5588

FORMALITIES LETTER



OC000000013465335

Date Mailed: 08/06/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450

Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE